Streetbeat News

Price Targets

RMBL

Wedbush analyst Seth Basham maintains an Outperform rating on RumbleON (NASDAQ:RMBL) but lowers the price target from $12 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 1:47 pm

PRPL

Wedbush analyst Seth Basham maintains an Outperform rating on Purple Innovation (NASDAQ:PRPL) but lowers the price target from $3.5 to $3.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 1:46 pm

VTNR

Northland Capital Markets has maintained an Outperform rating on Vertex Energy (NASDAQ:VTNR) but lowered the price target from $15 to $9.5.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 10, 2023 | 1:45 pm

WMG

Goldman Sachs analyst Stephen Laszczyk maintains a Buy rating on Warner Music Group (NASDAQ:WMG) and raises the price target from $35 to $40.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 1:45 pm

SKX

Wedbush analyst Tom Nikic has reiterated an Outperform rating on Skechers USA (NYSE:SKX) and maintained a $59 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 1:45 pm

SRRK

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Scholar Rock Holding (NASDAQ:SRRK) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 1:44 pm

UWMC

Goldman Sachs analyst Ryan Nash maintains a Neutral rating on UWM Holdings (NYSE:UWMC) and raises the price target from $6 to $6.75.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 1:44 pm

PENN

Canaccord Genuity analyst Jason Tilchen maintains a 'Buy' rating on PENN Entertainment but lowers the price target from $44 to $38.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 10, 2023 | 1:44 pm

ACET

Wedbush analyst Robert Driscoll has reiterated an 'Outperform' rating on Adicet Bio (NASDAQ:ACET) and maintained a $17 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 1:43 pm

JANX

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 1:42 pm